PDL BioPharma Inc (PDLI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PDL BioPharma Inc (PDLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012231
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to late-stage public and private healthcare companies. PDL provides companies, academic institutions, and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc (PDLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 12
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 14
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 16
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 17
Equity Offering 19
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 19
Debt Offering 20
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 20
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 21
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 23
PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For US$155 Million 24
PDL BioPharma Inc – Key Competitors 25
PDL BioPharma Inc – Key Employees 26
PDL BioPharma Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 02, 2017: PDL BioPharma Announces Third Quarter 2017 Financial Results 28
Aug 03, 2017: PDL BioPharma Announces Second Quarter 2017 Financial Results 31
May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 33
Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 35
Nov 03, 2016: PDL BioPharma Announces Third Quarter 2016 Financial Results 37
Aug 04, 2016: PDL BioPharma Announces Second Quarter 2016 Financial Results 39
May 04, 2016: PDL BioPharma Announces First Quarter 2016 Financial Results 42
Feb 22, 2016: PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results 43
Corporate Communications 45
Sep 11, 2017: PDL BioPharma Appoints Dominique Monnet as President 45
Legal and Regulatory 46
Dec 19, 2016: Lensar Strategic Restructure In Partnership With Pdl Biopharma
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PDL BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 12
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 14
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 16
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 17
Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 19
PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 20
PDL BioPharma Completes Public Offering Of Notes Due 2018 For US$300 Million 21
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 23
PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For US$155 Million 24
PDL BioPharma Inc, Key Competitors 25
PDL BioPharma Inc, Key Employees 26
PDL BioPharma Inc, Subsidiaries 27

★海外企業調査レポート[PDL BioPharma Inc (PDLI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • InterContinental Hotels Group Plc:企業のM&A・事業提携・投資動向
    InterContinental Hotels Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's InterContinental Hotels Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Grande Asset Hotels And Property Pcl
    Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report Summary Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Boyd Gaming Corporation:企業のM&A・事業提携・投資動向
    Boyd Gaming Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boyd Gaming Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Bunzl plc (BNZL):企業の財務・戦略的SWOT分析
    Bunzl plc (BNZL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • MEC Holding GmbH:企業の戦略的SWOT分析
    MEC Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Bengal Energy Ltd (Bengal Energy), formerly Avery Resources Inc is an oil and gas exploration and production company that acquires, explores, and produces prospective light oil-weighted onshore assets …
  • Care Hospitals:製薬・医療:M&Aディール及び事業提携情報
    Summary Care Hospitals is a healthcare service provider that offers medical care services. The center operates through its specialty departments such as anesthesiology, clinical psychology, obstetrics and gynecology, dietetics and nutrition, ophthalmology and hematology, emergency and general medici …
  • Qualcomm Inc (QCOM):企業の財務・戦略的SWOT分析
    Qualcomm Inc (QCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • nib Holdings Limited:企業の戦略・SWOT・財務情報
    nib Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary nib Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CompuGroup Medical Deutschland AG (COP):医療機器:M&Aディール及び事業提携情報
    Summary CompuGroup Medical Deutschland AG (CGM) is a provider of medical software products and healthcare services. The company provides products such as communication solutions, software assisted medicine, dentist information systems, ambulatory information systems, drug safety and patient marketin …
  • Camden Property Trust:企業の戦略・SWOT・財務情報
    Camden Property Trust - Strategy, SWOT and Corporate Finance Report Summary Camden Property Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Midas Group Ltd:企業の戦略・SWOT・財務分析
    Midas Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Midas Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Pacific Mutual Holding Company:企業の戦略的SWOT分析
    Pacific Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Cheil Worldwide Inc. (030000):企業の財務・戦略的SWOT分析
    Cheil Worldwide Inc. (030000) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Doosan Heavy Industries & Construction Co Ltd (034020)-エネルギー分野:企業M&A・提携分析
    Summary Doosan Heavy Industries & Construction Co., Ltd. (Doosan Heavy Industries), a subsidiary of Doosan Corporation, is a power plant equipment manufacturer. It offers integrated equipment and solutions for power and water plants. The company’s major products include boilers, generators, engines, …
  • MILEI GmbH:企業の戦略・SWOT・財務情報
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Consun Pharmaceutical Group Ltd (1681):製薬・医療:M&Aディール及び事業提携情報
    Summary Consun Pharmaceutical Group Ltd (Consun Pharmaceutical) is a pharmaceutical company that manufactures and distributes Chinese medicines. The company offers gadopentetate injection, cetirizine hydrochloride oral solution, iron dextran oral solution, uremic granules, compound amino acid inject …
  • Calfrac Well Services Ltd (CFW):石油・ガス:M&Aディール及び事業提携情報
    Summary Calfrac Well Services Ltd (Calfrac) is an oilfield services company. It operates as an independent provider of specialized oilfield services. The company offers various specialized services such as hydraulic fracture-stimulation, coiled tubing, well simulation, fracturing, acidizing, frac de …
  • Huber+Suhner AG (HUBN):企業の財務・戦略的SWOT分析
    Huber+Suhner AG (HUBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Naval Group:戦略・SWOT・企業財務分析
    Naval Group - Strategy, SWOT and Corporate Finance Report Summary Naval Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆